# Safety and Efficacy Evaluation of Next-generation CD19-UCART

> **NCT05381181** · PHASE1 · UNKNOWN · sponsor: **Bioray Laboratories** · enrollment: 20 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** CD19-UCART

## Key facts

- **NCT ID:** NCT05381181
- **Lead sponsor:** Bioray Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-20
- **Primary completion:** 2024-05-30
- **Final completion:** 2026-05-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05381181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05381181, "Safety and Efficacy Evaluation of Next-generation CD19-UCART". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT05381181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*